Key facts
- Verve Medical’s last known valuation is $64.0M (Aug 2020).
- It has raised $11.2M across 2 recorded rounds; the latest was Seed Round ($470K) in Oct 2016.
- Notable investors include Flinn Foundation, BioAccel, HM Venture Partners, LongRiver Investments.
- Verve Medical has filed 3 Form Ds with the SEC since 2015, most recently Jan 2017 ($470K sold to 5 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Verve Medical
Funding rounds
2 roundsAbout Verve Medical
Developer of renal denervation devices intended to reduce hypertension. The company's devices reduce systolic blood pressure for treating hypertension by reducing the sympathetic nervous system drive through renal denervation, enabling patients to reduce the risk related to stroke and heart disease.
- Sector
- Healthcare
- HQ
- Phoenix, AZ, United States
- Founded
- 2010
- Employees
- 8
- Website
- verve-medical.com/
- Ownership
- Privately Held (backing)
Verve Medical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Verve Medical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Verve Medical in its N-PORT filings yet. We sweep new filings monthly.